Latest news and press releases about Cogent Biosciences, Inc. (COGT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST).
Price
| Price | $32.54 |
| Market Cap | $5.6B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 10.45 |
| EV / EBITDA | -15.17 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -72.57% |
| Return on Invested Capital | -50.09% |
| Return on Assets | -45.20% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AGIO · DNLI · ETNB · GLPG · IBRX · LQDA · OCUL
Explore sector: Healthcare · Biotechnology
More sections of COGT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks